Adaptation of HIV-1 to rhTrim5α-mediated restriction in vitro

Virology

Volumn 486, Issue , 2015, Pages 239-247

  Setiawan, Laurentia C ^a   Kootstra, Neeltje A ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Escape mutations; HIV 1; Reverse transcriptase; Trim5 ; Viral capsid; Viral fitness

Indexed keywords

CAPSID PROTEIN; GAG PROTEIN; RECOMBINANT TRIPARTITE MOTIF PROTEIN 5; TRIPARTITE MOTIF PROTEIN 5; UNCLASSIFIED DRUG; CARRIER PROTEIN; POL PROTEIN; PROTEIN; TRIM5 PROTEIN, HUMAN; TRIM5(ALPHA) PROTEIN, RHESUS MONKEY;

AMINO ACID SUBSTITUTION; ARTICLE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; VIRUS GENOME; VIRUS ISOLATION; VIRUS MUTATION; VIRUS REPLICATION; AMINO ACID SEQUENCE; ANIMAL; GENETICS; HOST PATHOGEN INTERACTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; MOLECULAR GENETICS; MUTATION; PHYSIOLOGY; RHESUS MONKEY; VIROLOGY;

AMINO ACID SEQUENCE; ANIMALS; CARRIER PROTEINS; GENE PRODUCTS, GAG; HIV INFECTIONS; HIV-1; HOST-PATHOGEN INTERACTIONS; HUMANS; MACACA MULATTA; MOLECULAR SEQUENCE DATA; MUTATION; POL GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; PROTEINS; VIRUS REPLICATION;

EID: 84944051737     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2015.09.017     Document Type: Article

References (45)

1. Allers K., Hutter G., Hofmann J., Loddenkemper C., Rieger K., Thiel E., Schneider T. Evidence for the cure of HIV infection by CCR5{Delta}32/{Delta}32 stem cell transplantation. Blood 2011, 117:2791-2799.
2. Anderson J., Akkina R. TRIM5 alpha(rh) expression restricts HIV-1 infection in lentiviral vector-transduced CD34(+)-cell-derived macrophages. Mol. Ther. 2005, 12:687-696.
3. Anderson J., Akkina R. Complete knockdown of CCR5 by lentiviral vector-expressed siRNAs and protection of transgenic macrophages against HIV-1 infection. Gene Ther. 2007, 14:1287-1297.
4. Anderson J., Akkina R. Human immunodeficiency virus type 1 restriction by human-rhesus chimeric tripartite motif 5 alpha (TRIM 5 alpha) in CD34(+) cell-derived macrophages in vitro and in T cells in vivo in severe combined immunodeficient (SCID-hu) mice transplanted with human fetal tissue. Hum. Gene Ther. 2008, 19:217-228.
5. Bailey J.R., O'Connell K., Yang H.C., Han Y., Xu J., Jilek B., Williams T.M., Ray S.C., Siliciano R.F., Blankson J.N. Transmission of HIV-1 from a patient who developed AIDS to an elite suppressor. J.Virol. 2008, 82:7395-7410.
6. Battivelli E., Migraine J., Lecossier D., Yeni P., Clavel F., Hance A.J. Gag cytotoxic T lymphocyte escape mutations can increase sensitivity of HIV-1 to Human TRIM5 alpha, linking intrinsic and acquired immunity. J. Virol. 2011, 85:11846-11854.
7. Berkhout B. Toward a durable anti-HIV gene therapy based on RNA Interference. Oligonucleotide Ther. 2009, 1175:3-14.
8. Chatterji U., Bobardt M.D., Stanfield R., Ptak R.G., Pallansch L.A., Ward P.A., Jones M.J., Stoddart C.A., Scalfaro P., Dumont J.M., Besseghir K., Rosenwirth B., Gallay P.A. Naturally occurring capsid substitutions render HIV-1 cyclophilin A independent in human cells and TRIM-cyclophilin-resistant in Owl monkey cells. J.Biol.Chem. 2005, 280:40293-40300.
9. Cohen J. Halting Hiv/Aids epidemics. Science 2011, 334:1338-1340.
10. Dean M., Carrington M., Winkler C., Huttley G.A., Smith M.W., Allikmets R., Goedert J.J., Buchbinder S.P., Vittinghoff E., Gomperts E., Donfield S., Vlahov D., Kaslow R., Saah A., Rinaldo C., Detels R., O'Brien S.J. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia growth and development study, multicenter AIDS cohort study, multicenter hemophilia Cohort study, San Francisco city Cohort, ALIVE study. Science 1996, 273:1856-1862.
11. DiGiusto D.L., Krishnan A., Li L.J., Li H.T., Li S., Rao A., Mi S., Yam P., Stinson S., Kalos M., Alvarnas J., Lacey S.F., Yee J.K., Li M.J., Couture L., Hsu D., Forman S.J., Rossi J.J., Zaia J.A. RNA-based gene therapy for HIV with lentiviral vector-modified CD34(+) cells in patients undergoing transplantation for AIDS-Related lymphoma. Sci. Transl. Med. 2010, 2.
12. Dull T., Zufferey R., Kelly M., Mandel R.J., Nguyen M., Trono D., Naldini L. A third-generation lentivirus vector with a conditional packaging system. J. Virol. 1998, 72:8463-8471.
13. Edo-Matas D., van Dort K.A., Setiawan L.C., Schuitemaker H., Kootstra N.A. Comparison of in vivo and in vitro evolution of CCR5 to CXCR4 coreceptor use of primary human immunodeficiency virus type 1 variants. Virology 2011, 412:269-277.
14. Finzi D., Blankson J., Siliciano J.D., Margolick J.B., Chadwick K., Pierson T., Smith K., Lisziewicz J., Lori F., Flexner C., Quinn T.C., Chaisson R.E., Rosenberg E., Walker B., Gange S., Gallant J., Siliciano R.F. Latent infection of CD4+ T cells provides a mechanism for lifelong persistance of HIV-1, even in patients on effective combination therapy. Nat. Med. 1999, 5:512-517.
15. Gijsbers E.F., Feenstra K.A., van Nuenen A.C., Navis M., Heringa J., Schuitemaker H., Kootstra N.A. HIV-1 replication fitness of HLA-B 57/58:01 CTL escape variants is restored by the accumulation of compensatory mutations in gag. PLoS.One. 2013, 8:e81235.
16. Granier C., Battivelli E., Lecuroux C., Venet A., Lambotte O., Schmitt-Boulanger M., Delaugerre C., Molina J.M., Chakrabarti L.A., Clavel F., Hance A.J. Pressure from TRIM5 alpha contributes to control of HIV-1 replication by individuals expressing protective HLA-B alleles. J. Virol. 2013, 87:10368-10380.
17. Hutter G., Nowak D., Mossner M., Ganepola S., Mussig A., Allers K., Schneider T., Hofmann J., Kucherer C., Blau O., Blau I.W., Hofmann W.K., Thiel E. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N. Engl. J. Med. 2009, 360:692-698.
18. Ikeda Y., Ylinen L.M., Kahar-Bador M., Towers G.J. Influence of gag on human immunodeficiency virus type 1 species-specific tropism. J. Virol. 2004, 78:11816-11822.
19. Jansen C.A., Kostense S., Vandenberghe K., Nanlohy N.M., De Cuyper I.M., Piriou E., Manting E.H., Miedema F., van Baarle D. High responsiveness of HLA-B57-restricted Gag-specific CD8+ T cells in vitro may contribute to the protective effect of HLA-B57 in HIV-infection. Eur. J. Immunol. 2005, 35:150-158.
20. Kootstra N.A., Matsumura R., Verma I.M. Efficient production of human FVIII in hemophilic mice using lentiviral vectors. Mol.Ther. 2003, 7:623-631.
21. Kootstra N.A., Munk C., Tonnu N., Landau N.R., Verma I.M. Abrogation of postentry restriction of HIV-1-based lentiviral vector transduction in simian cells. Proc. Natl. Acad. Sci. USA 2003, 100:1298-1303.
22. Kootstra N.A., Navis M., Beugeling C., van Dort K.A., Schuitemaker H. The presence of the Trim5alpha escape mutation H87Q in the capsid of late stage HIV-1 variants is preceded by a prolonged asymptomatic infection phase. AIDS 2007, 21:2015-2023.
23. Kootstra N.A., Schuitemaker H. Phenotype of HIV-1 lacking a functional nuclear localization signal in matrix protein of gag and Vpr is comparable to wild-type HIV-1 in primary macrophages. Virology 1999, 253:170-180.
24. Li Y., Li X., Stremlau M., Lee M., Sodroski J. Removal of arginine 332 allows human TRIM5alpha to bind human immunodeficiency virus capsids and to restrict infection. J. Virol. 2006, 80:6738-6744.
25. Liu R., Paxton W.A., Choe S., Ceradini D., Martin S.R., Horuk R., MacDonald M.E., Stuhlmann H., Koup R.A., Landau N.R. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996, 86:367-377.
26. Maillard P.V., Zoete V., Michielin O., Trono D. Homology-based identification of capsid determinants that protect HIV1 from human TRIM5 alpha Restriction. J. Biol. Chem. 2011, 286:8128-8140.
27. Navis M., Matas D.E., Rachinger A., Koning F.A., van S.P., Kootstra N.A., Schuitemaker H. Molecular evolution of human immunodeficiency virus type 1 upon transmission between human leukocyte antigen disparate donor-recipient pairs. PLoS.One 2008, 3:e2422.
28. Navis M., Schellens I., van Baarle D., Borghans J., van Swieten P., Miedema F., Kootstra N., Schuitemaker H. Viral replication capacity as a correlate of HLA B57/B5801-associated nonprogressive HIV-1 infection. J. Immunol. 2007, 179:3133-3143.
29. Oberlin E., Amara A., Bachelerie F., Bessia C., Virelizier J.-L., Arenzana-Seisdedos F., Schwartz O., Heard J.-M., Clark-Lewis I., Legler D.F., Loetscher M., Baggiolini M., Moser B. The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line adapted HIV-1. Nature 1996, 382:833-835.
30. Pacheco B., Finzi A., Stremlau M., Sodroski J. Adaptation of HIV-1 to cells expressing rhesus monkey TRIM5 alpha. Virology 2010, 408:204-212.
31. Palella F.J., Delaney K.M., Moorman A.C., Loveless M.O., Fuhrer J., Satten G.A., Aschman D.J., Holmberg S.D. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N. Engl. J. Med. 1998, 338:853-860.
32. Pham Q.T., Bouchard A., Grutter M.G., Berthoux L. Generation of human TRIM5 alpha mutants with high HIV-1 restriction activity. Gene Ther. 2010, 17:859-871.
33. Rits M.A., van Dort K.A., Munk C., Meijer A.B., Kootstra N.A. Efficient transduction of simian cells by HIV-1-based lentiviral vectors that contain mutations in the capsid protein. Mol. Ther. 2007, 15:930-937.
34. Rold C.J., Aiken C. Proteasomal degradation of TRIM5alpha during retrovirus restriction. PLoS Pathog. 2008, 4:e1000074.
35. Sakuma R., Noser J.A., Ohmine S., Ikeda Y. Rhesus monkey TRIM5 alpha restricts HIV-1 production through rapid degradation of viral Gag polyproteins. Nat. Med. 2007, 13:631-635.
36. Samson M., Libert F., Doranz B.J., Rucker J., Liesnard C., Farber C.M., Saragosti S., Lapoumeroulie C., Cognaux J., Forceille C., Muyldermans G., Verhofstede C., Burtonboy G., Georges M., Imai T., Rana S., Yi Y., Smyth R.J., Collman R.G., Doms R.W., Vassart G., Parmentier M. Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996, 382:722-725.
37. Senserrich J., Pauls E., Armand-Ugon M., Clotet-Codina I., Moncunill G., Clotet B., Este J.A. HIV-1 resistance to the anti-HIV activity of a shRNA targeting a dual-coding region. Virology 2008, 372:421-429.
38. Soll S.J., Wilson S.J., Kutluay S.B., Hatziioannou T., Bieniasz P.D. Assisted Evolution Enables HIV-1 to Overcome a High TRIM5 alpha-Imposed Genetic Barrier to Rhesus Macaque Tropism. Plos Pathog. 2013, 9.
39. Stremlau M., Owens C.M., Perron M.J., Kiessling M., Autissier P., Sodroski J. The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys. Nature 2004, 427:848-853.
40. Tersmette M., Winkel I.N., Groenink M., Gruters R.A., Spence P., Saman E., van der Groen G., Miedema F., Huisman J.G. Detection and subtyping of HIV-1 isolates with a panel of characterized monoclonal antibodies to HIV-p24 gag. Virology 1989, 171:149-155.
41. Veillette M., Bichel K., Pawlica P., Freund S.M.V., Plourde M.B., Pham Q.T., Reyes-Moreno C., James L.C., Berthoux L. The V86M mutation in HIV-1 capsid confers resistance to TRIM5 alpha by abrogation of cyclophilin A-dependent restriction and enhancement of viral nuclear import. Retrovirology 2013, 10.
42. Walker J.E., Chen R.X., Mcgee J., Nacey C., Pollard R.B., Abedi M., Bauer G., Nolta J.A., Anderson J.S. Generation of an HIV-1-resistant immune system with CD34(+) hematopoietic stem cells transduced with a triple-combination anti-HIV lentiviral vector. J. Virol. 2012, 86:5719-5729.
43. Wong J.K., Hezareh M., Günthard H.F., Havlir D., Ignacio C.C., Spina C.A., Richman D.D. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 1997, 278:1291-1295.
44. Yang Y., Fricke T., Diaz-Griffero F. Inhibition of reverse transcriptase activity increases stability of the HIV-1 core. J. Virol. 2013, 87:683-687.
45. Yap M.W., Nisole S., Stoye J.P. A single amino acid change in the SPRY domain of human Trim5alpha leads to HIV-1 restriction. Curr. Biol. 2005, 15:73-78.